Illuminating Cellular Mysteries: The Research Frontiers of Dr. Jin Wang's Group at Baylor College of Medicine
The intricate dance of molecules within living cells governs health and disease, presenting a persistent challenge for scientific understanding and therapeutic intervention. At the forefront of deciphering these complex biological processes is the research group led by Dr. Jin Wang at Baylor College of Medicine. Dr. Wang's laboratory is dedicated to pioneering innovative tools and methodologies that enable unprecedented insights into cellular function, with a particular focus on redox signaling, covalent therapeutics, and the development of advanced imaging and proteomic techniques. This article delves into the significant contributions of Dr. Wang's group, exploring their groundbreaking work in quantitative real-time imaging of crucial cellular molecules, the development of novel therapeutic strategies targeting protein-protein interactions and cellular resistance, and the creation of sophisticated platforms for profiling drug kinetics and selectivity.
Unveiling the Dynamics of Cellular Redox State: Quantitative Imaging of Glutathione
Redox signaling molecules, though often present at low concentrations ranging from micromolar to submicromolar levels, play indispensable roles in a vast array of biological pathways and disease mechanisms. Accurately measuring these low-abundant analytes, however, has historically been hampered by the limitations in sensitivity and quantitative capability of existing methods. This challenge has spurred the Wang laboratory to develop novel approaches for their detection.
A significant breakthrough from the group is the development of a reversible reaction-based fluorescent probe, designated as RealThiol (RT). This innovative probe is designed to quantitatively monitor real-time glutathione dynamics within living cells. Glutathione, a critical endogenous antioxidant, plays many important roles in biological processes, yet the dynamic changes of its concentrations in living cells have remained largely unknown. Using RT, researchers have been able to observe enhanced antioxidant capability in activated neurons and dynamic glutathione changes during ferroptosis, a form of programmed cell death. The RealThiol probe is thus a versatile tool that can be employed for both confocal microscopy and flow cytometry-based high-throughput quantification of glutathione levels in single cells. This work, published in Antioxidants & Redox Signaling and Nature Communications, provides a powerful means to understand the delicate balance of cellular redox states and their implications in health and disease. Further work has also focused on the quantitative real-time imaging of glutathione with subcellular resolution, enabling a deeper understanding of its localized roles within the cell.
Beyond glutathione, the group has also explored novel chemically induced amplifiable systems for quantifying other low-abundance redox signaling molecules in living cells. Utilizing hydrogen peroxide (H2O2) as a proof-of-concept analyte, they developed a probe that quantifies cellular peroxide levels by integrating the NanoBiT system with androgen receptor dimerization as a reporting mechanism. This system demonstrated a highly sensitive response to cellular peroxide changes, both those arising endogenously and those introduced exogenously, underscoring the laboratory's commitment to advancing the quantitative measurement of vital cellular signaling molecules.
Revolutionizing Therapeutics: Covalent Inhibitors and Proteolysis Targeting Chimeras (PROTACs)
The development of targeted therapeutics has revolutionized medicine, and Dr. Wang's group is actively contributing to this field through innovative approaches to drug discovery and development. Covalent inhibitors, an emerging class of therapeutics, offer the potential for prolonged target engagement and enhanced efficacy. However, methods to comprehensively profile their binding kinetics and selectivity across the proteome have been limited.
Read also: Baylor's Notable Alumni
To address this, the Wang laboratory introduced COOKIE-Pro (COvalent Occupancy KInetic Enrichment via Proteomics). This unbiased method is designed for quantifying irreversible covalent inhibitor binding kinetics on a proteome-wide scale. COOKIE-Pro employs a two-step incubation process coupled with mass spectrometry-based proteomics to determine kinact and KI values for covalent inhibitors against both on-target and off-target proteins. The utility of COOKIE-Pro was validated using Bruton's tyrosine kinase (BTK) inhibitors, spebrutinib and ibrutinib, accurately reproducing known kinetic parameters and identifying both expected and previously unreported off-targets. Notably, the method revealed that spebrutinib exhibits over 10-fold higher potency for TEC kinase compared to its intended target BTK. To demonstrate the method's suitability for high-throughput screening, a streamlined two-point strategy was applied to a library of 16 covalent fragments. This approach successfully generated thousands of kinetic profiles, enabling the quantitative decoupling of intrinsic chemical reactivity from binding affinity at scale and validating the method's broad applicability.
Furthermore, the group is exploring the potential of proteolysis targeting chimera (PROTAC) technology. PROTACs are bifunctional molecules that recruit target proteins to E3 ubiquitin ligases, leading to their proteasomal degradation. While current efforts in the PROTAC field largely focus on ligase selection, binding affinity optimization, and linker design, the cellular uptake of PROTACs, owing to their large molecular weights, remains a significant challenge.
Through comparative studies examining how different warhead chemistries-reversible noncovalent (RNC), reversible covalent (RC), and irreversible covalent (IRC) binders-affect the degradation of Bruton’s Tyrosine Kinase (BTK), the Wang laboratory serendipitously discovered that cyano-acrylamide-based reversible covalent chemistry can significantly enhance the intracellular accumulation and target engagement of PROTACs. This led to the development of RC-1, a reversible covalent BTK PROTAC. RC-1 exhibits high target occupancy comparable to its corresponding kinase inhibitor and demonstrates effectiveness as a dual functional inhibitor and degrader, representing a novel mechanism of action for PROTACs.
The scaffolding function of receptor interacting protein kinase 1 (RIPK1) has emerged as a critical factor conferring intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), positioning it as a promising target for improving cancer immunotherapies. Addressing the challenge posed by a poorly defined binding pocket within the intermediate domain of RIPK1, the group harnessed PROTAC technology to develop a RIPK1 degrader, LD4172. LD4172 has demonstrated potent and selective RIPK1 degradation both in vitro and in vivo. The degradation of RIPK1 by LD4172 triggers immunogenic cell death, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy in preclinical models, highlighting its therapeutic potential.
Tackling "Undruggable" Targets: Protein-Protein Interactions and Small Molecule Inhibitors
Protein-protein interactions (PPIs) are fundamental to nearly all biological processes and represent a crucial class of targets for therapeutic development. However, disrupting PPIs with small-molecule inhibitors (SMIs) is notoriously challenging and often considered an "undruggable" endeavor. The Wang laboratory has made significant strides in overcoming this hurdle.
Read also: Avoiding Med School Application Mistakes
They developed a cell-based functional assay for high-throughput screening to identify SMIs for steroid receptor coactivator-3 (SRC-3 or AIB1), a large and predominantly unstructured nuclear protein. Without any initial structural information for SRC-3, the screening identified SI-2 as a highly promising SMI. SI-2 adheres to Lipinski's rule of five for drug-like molecules, possesses a half-life of one hour in pharmacokinetic studies, and exhibits reasonable oral availability in mice. As an SRC-3 SMI, SI-2 effectively reduces the transcriptional activities and protein concentrations of SRC-3 within cells through direct physical interactions. Crucially, it selectively induces breast cancer cell death with IC50 values in the low nanomolar range (3-20 nM) without affecting the viability of normal cells. Furthermore, SI-2 significantly inhibits primary tumor growth and reduces SRC-3 protein levels in a breast cancer mouse model. Toxicological studies indicated minimal acute cardiotoxicity based on hERG channel blocking assays and unappreciable chronic toxicity to major organs upon histological analysis, underscoring the therapeutic potential and safety profile of SI-2.
Novel Chemistries for Drug Delivery and Beyond
Beyond therapeutic targeting, the Wang group also explores novel chemical functionalities for advanced drug delivery systems. Disulfide bonds have traditionally been the sole widely utilized functionality to serve as a reduction-responsive trigger in drug delivery. The laboratory has introduced thioester as a novel thiol-responsive chemistry for drug delivery. The reactivity of thioesters can be conveniently modulated by selecting the appropriate steric environment around the ester linkage. Compared to disulfides, thioesters are synthesized more readily and offer an order of magnitude broader kinetic tunability. This innovation opens new avenues for developing drug delivery systems that are precisely controlled by the cellular redox environment.
A Foundation in Spectroscopic and Nanoparticle Research
Dr. Jin Wang's scientific journey began with a strong foundation in organic chemistry and physical chemistry. He obtained his Ph.D. in Organic Chemistry from The Ohio State University under the guidance of Dr. Matthew Platz in 2007. During his doctoral studies, he applied ultrafast spectroscopy to investigate organic reactive intermediates, gaining expertise in computational chemistry, organic synthesis, and photochemistry. His prolific graduate tenure resulted in 13 first-authored publications, with an impressive 8 appearing in the prestigious Journal of the American Chemical Society (JACS). Following his Ph.D., he completed three years of postdoctoral training with Dr. Joseph DeSimone at the University of North Carolina at Chapel Hill. This postdoctoral work provided him with valuable experience in nanoparticle design and its applications in nanomedicine, including research on more effective nanomedicines through particle design and the complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies.
Read also: Affording Baylor University
tags: #baylor #college #of #medicine #jin #wang
